



## **Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature**

SCIENCE

[Abstracts](#)

Key Take-Away:

Denosumab is human monoclonal antibody used in the treatment of osteoporosis. A systematic review of literature had been conducted in this study using various databases in order to evaluate effect of denosumab in rheumatoid arthritis patients. It was confirmed that denosumab was effective in declining joint erosion at a time period of 6 and 12 months.

ABSTRACT:

Background:

The aim of this study was to evaluate the structural effect of denosumab on patients with rheumatoid arthritis (RA).

Methods:

A systematic review was undertaken from the literature in the following databases: Pub Med, Cochrane, Web of Science, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform.

All studies evaluating the structural effect of denosumab on RA and meeting predefined criteria were included. Data regarding disease activity, progression of joint damage, joint space narrowing, and safety were recorded.

[Expand section](#)

Results:

Among 168 studies identified, only 4 were finally included in this review, involving a total of 687 patients. These 4 studies showed that denosumab is effective on joint damage at 6 and 12 months as compared to placebo, alendronate, and biological disease-modifying anti-rheumatic drugs (bDMARDs) alone.

No effect was observed in terms of joint space narrowing, and DAS28 and HAQ scores remained unchanged. No case of osteonecrosis of the jaw or atypical fracture was recorded, and safety was similar in both denosumab and control groups.

[Expand section](#)

Conclusion:

Denosumab appears to be effective on joint erosion at 6 and 12 months in patients with RA meeting the ACR criteria, treated or not by a biologic, with excellent safety.

Source: Clin Rheumatol. 2017 Jul 1

Link to the source: <https://www.ncbi.nlm.nih.gov/pubmed/28669103>

Original title of article: Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature



Authors: Gonçalo Boleto et al

[Expand section](#)

Therapeutic, Denosumab, Rheumatoid Arthritis, Joints, Monoclonal Antibody, Systematic Review, Efficacy, Safety, DAS28, HAQ Scores